NotebookLM-buhler

1. Identify all drugs, class, and MOA of presented agents

Amphetamines:

• Drugs: Dextroamphetamine/Amphetamine (Adderall), Lisdexamfetamine (Vyvanse — prodrug of dextroamphetamine)

• Class: Psychomotor Stimulants / Amphetamines.

• MOA: Reversal of dopamine (DAT) and norepinephrine (NET) transporters, vesicle loading, and inhibition of MAO-A2. Produces the strongest global increase in NE and DA2.

Methylphenidates:

• Drugs: Methylphenidate (Ritalin, Concerta, Daytrana transdermal), Dexmethylphenidate (Focalin, Focalin XR).

• Class: Psychomotor Stimulants / Methylphenidates

• MOA: DAT and NET inhibition, vesicle redistribution Produces a strong increase in NE and DA2.

• Non-Stimulant ADHD Agent (NRTI):

  • Drug: Atomoxetine (Strattera).

  • Class: Non-stimulant / NRTI (Norepinephrine Reuptake Transporter Inhibitor).

  • MOA: NET interference in the Prefrontal Cortex (PFC), which indirectly increases both NE and DA specifically in the PFC.

Wake-Promoting Agents:

• Drugs: Modafinil (Provigil), Armodafinil (Nuvigil)

• Class: Wake-Promoting Agents.

• MOA: Atypical DAT inhibitor, selectively increasing DA in sleep/wake regions (hypothalamus).

• Selective Histamine H3 Receptor Agent:

  • Drug: Pitolisant (Wakix).

  • Class: Presynaptic H3 Receptor Antagonist / Inverse Agonist (Wake Agent).

  • MOA: Blocks presynaptic H3 autoreceptors to disinhibit and increase histamine release into the synapse.

DNRI Wake Agent:

• Drug: Solriamfetol (Sunosi).

• Class: Dopamine and Norepinephrine Reuptake Inhibitor (DNRI).

• MOA: Mild global increase in DA and NE via reuptake inhibition.

GABAB Agonist:

• Drug: Sodium oxybate (Xyrem, Lumryz).

• Class: GABAB receptor agonist.

• MOA: GABAB activation that alters sleep architecture to consolidate night sleep and reduce daytime sleepiness.

Dual Orexin Receptor Antagonists (DORAs):

• Drugs: Suvorexant (Belsomra), Lemborexant (Dayvigo), Daridorexant (Quviviq).

• Class: Dual Orexin Receptor Antagonists / Sleep Agents112.

• MOA: Antagonizes orexin receptors (OX1/OX2), blocking wake-promoting orexin signaling.

review/sleep

Benzodiazepines:

• Drugs: Triazolam (Halcion), Temazepam (Restoril).

• Class: Benzodiazepines / Sedative-Hypnotics

• MOA: Positive allosteric potentiator of GABA binding at GABAA receptors (requires endogenous GABA).

Z-drugs:

• Drugs: Zolpidem (Ambien), Eszopiclone (Lunesta), Zaleplon (Sonata).

• Class: Z-drugs / Non-benzodiazepine hypnotics1more_horiz.

• MOA: Allosteric potentiator of GABA binding at a selective subset of GABAA receptors in sleep/wake centers

Melatonin Agonist:

• Drug: Ramelteon (Rozerem).

• Class: Melatonin receptor agonist.

• MOA: Agonist at melatonin receptors (MT1/MT2) to regulate circadian rhythm.

Antihistamines (Sedating):

• Drug: Diphenhydramine (Benadryl).

• Class: Sedating H1 Antihistamines.

• MOA: Blocks postsynaptic H1 receptors to suppress wakefulness.

2. Physiological effects and dose dependence of psychomotor stimulants

Psychomotor stimulant effects involve both central (brain) and autonomic/motor actions:

• Brain Effects: Increased alertness, focus, energy, euphoria, addiction potential, and appetite suppression.

• Autonomic & Motor Effects: Motor hyperactivity, tremor, respiratory/cardiovascular stimulation (increased HR, increased BP), dizziness, and headache.

Dose Dependence:

• Low Dose: Increased alertness, focus, and energy.

• High Dose: Decreased focus, irritability, insomnia, rapid speech, and motor jitter/hyperactivity.

• Very High Dose: Psychotic reactions and convulsions.

3. Drug properties leading to addiction vs. tolerance and dependence

• Tolerance: A neuroadaptive decrease in response to a drug over time, requiring higher doses to achieve the same effect.

• Physical/Physiologic Dependence: An altered physiological state where continued drug presence is required to prevent a physical withdrawal syndrome.

• Addiction: Compulsive drug-seeking and drug-using behavior despite negative consequences, primarily driven by rapid dopamine surges in central reward pathways

4. Stimulated vigilance vs. normal wakefulness

• Stimulated Vigilance: Produced by stimulants (e.g., caffeine, amphetamines) that increase monoamines globally across the brain. Characterized by "external vigilance", high autonomic arousal, hyperarousal, false alertness, and lower quality cognition, memory, and focus.

• Normal Wakefulness: Produced naturally or activated by wake-promoting agents (e.g., modafinil, armodafinil) that balance orexin, GABA, and histamine in hypothalamic sleep-wake centers. Characterized by "internal vigilance", calm wakefulness, high-quality alertness, and effective cognition and memory.

5. Main theory of ADHD and drug action on target regions

• Main Theory: ADHD is caused by decreased monoamine levels (NE and DA) in specific Prefrontal Cortex (PFC) regions responsible for cognitive control, executive function, and in reward pathways.

• Target Regions: Under-active PFC regions include motor planning/inhibition centers, attention centers, behavioral impulse control centers, and cognitive centers.

• Drug Mechanisms: ADHD medications increase synaptic NE and DA levels in these under-active PFC centers, which restores top-down activation to improve focus, impulse control, and executive function.

6. How low NE and DA cause "hyperactive" clinical symptoms

• Impulse control and motor inhibition centers in the PFC require adequate NE and DA stimulation to exert inhibitory control.

• Low NE and DA leave these inhibitory centers under-active3132. Without sufficient top-down prefrontal inhibition, unwanted motor behavior and impulsive urges go unsuppressed, manifesting clinically as locomotor hyperactivity (fidgeting, pacing) and behavioral impulsivity.

7. Significance of drug action globally vs. PFC vs. sleep/wake regions

• Global Action (e.g., Amphetamines, Methylphenidates): Elevates monoamines throughout the brain and periphery. Improves focus but causes systemic cardiovascular side effects (increased HR/BP), motor jitter, hyperarousal, and high addiction risk due to striatal DA release.

• PFC-Preferential Action (e.g., Atomoxetine): Elevates NE and DA selectively in the Prefrontal Cortex via local NET blockade56. Improves executive function and focus without causing peripheral autonomic stimulation, wakefulness disruption, or addiction.

• Sleep/Wake Regions Only (e.g., Modafinil/Armodafinil, DORAs): Targets localized hypothalamic sleep-wake centers. Modafinil increases DA in wake centers to promote calm alertness without global stimulant side effects or addiction; DORAs block orexin in wake regions to promote sleep without global CNS depression or dependence.

8. Ranking ADHD drugs, wake-promoting agents, and DORAs

Drug Class	Specificity of Drug Targets	Regional Preferentialness	Potential Addictiveness
Amphetamines	Least specific (reverses DAT/NET, loads vesicles, inhibits MAO-A)	Poor / Global (acts across the whole brain/body)	Highly Addictive (especially at high doses)
Methylphenidates	Moderately specific (inhibits DAT/NET, redistributes vesicles)	Poor / Global (widespread brain/body action)	Addictive at high doses
Atomoxetine	Good specificity (NET inhibitor)	Preferential for PFC (increases NE & DA in PFC only)	Not Addictive
Modafinil / Armodafinil	Most specific (atypical DAT inhibitor)	Highly Preferential for Wake Regions (Hypothalamus)	Not Addictive
DORAs	Good/High specificity (Orexin OX1/OX2 antagonist)	Preferential for Sleep/Wake Regions	Not Addictive

10. Neurotransmitters/Hormones in Sleep vs. Wakefulness

• Promote Wakefulness: Histamine (HIST), Serotonin (5HT), Norepinephrine (NE), Dopamine (DA), Orexin (ORX).

• Promote Sleep: Melatonin, GABA.

11. Why Wakix is NOT an antihistamine despite being an H3R antagonist

• Pitolisant (Wakix) is an antagonist/inverse agonist at presynaptic H3 autoreceptors.

• Presynaptic H3 receptors normally provide inhibitory feedback to reduce histamine release.

• Blocking these presynaptic autoreceptors causes disinhibition, which increases histamine release into the synapse. Because histamine is a wake-promoting neurotransmitter, elevating histamine promotes wakefulness.

• Classic "antihistamines" (like diphenhydramine) block postsynaptic H1 receptors to prevent histamine action and cause sedation. Wakix does the opposite—it increases histamine signaling to keep patients awake.

12. Benzodiazepines, Z-drugs, and Melatonin Agonists summary

Benzodiazepines (Triazolam, Temazepam):

• Positive allosteric potentiators of GABA at GABAA receptors (has a safety ceiling alone).

• Act globally across most brain GABAA receptors, disrupt REM sleep architecture, have longer half-lives, and carry high risk for tolerance, physical dependence, and addiction.

Z-drugs (Zolpidem, Eszopiclone, Zaleplon):

• Allosteric potentiators at a selective subset of GABAA receptors in sleep/wake regions.

• Very rapid onset and short half-lives; preserve closer-to-normal sleep architecture with minimal REM disruption and low daytime residual sedation16more_horiz. Carry less tolerance and dependence16. Associated with complex sleep behaviors.

Melatonin Agonist (Ramelteon):

• Selective agonist at MT1 and MT2 melatonin receptors with no action at GABA receptors.

• Induces natural sleep patterns by shifting circadian rhythms without GABA-related sedation, motor impairment, or abuse potential

13. DORA Profile

• MOA: Dual Orexin Receptor Antagonist (blocks wake-promoting orexin peptides at OX1/OX2 receptors).

• Target Specificity: High / Good target specificity.

• Regional Specificity: High preferential activity for sleep/wake centers in the brain.

• Sedating: Yes, sleep-inducing hypnotic agents used for insomnia.

• Addictive: Not addictive.